With reference to its letter dated 7th February 2022 informing about the Board Meeting that was scheduled on 23 Feb 2022. The Meeting of Board of Directors commenced at 2.30 pm and concluded a 6.15 pm. Sanofi India has informed that the following items were considered and approved: Recommendation for payment of a final dividend of Rs 181 per equity share of Rs 10 each for the year ended 31st December 2021 and a special dividend of Rs 309 per equity share of Rs 10 each for the year ended 31st December 2021, after considering the slump sale and transfer of Company's nutraceuticals business during the year and reviewing the cash requirements for the Company's operations and Closure of Register of Members and Share Transfer Books from for determining the eligibility of shareholders for payment of the final dividend and the special dividend.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1644.30 |
| Dr. Reddys Lab | 1323.80 |
| Cipla | 1286.25 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2327.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: